News

Read about Dr Haifa Lyster's experience visiting UQCCR.

Grateful for the opportunity to spend time with Professor Jason Roberts’ Antimicrobial Optimisation research team at UQCCR. With the support of Dr Marta Ulldemolins, and Dr Patty Mitre I advanced my project on population pharmacokinetics and strengthened my PK/PD skills. I returned to Milan with new expertise, collaborations, and inspiring ideas for future research.

Meet one of CRE RESPOND's PhD students, Rob Oakley!

Optimal dosing of meropenem and piperacillin/tazobactam in critically ill patients receiving renal replacement therapy (RRT) is uncertain due to variable pharmacokinetics. We aimed to develop generalisable optimised dosing recommendations for these antibiotics.

NHMRC Emerging Leadership Fellow

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Louise's experience from his recent visit.

The objective of this First-in-Human Phase 1, double-blind, randomized, placebo-controlled study was to assess the pharmacokinetics (PK), safety, and tolerability of the dual targeting beta-lactamase inhibitor xeruborbactam (QPX7728) in healthy adults.

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Saskia's experience from his recent visit.

The Screening Antifungal Exposure in Intensive Care Units (SAFE-ICU) study, published in Intensive Care Medicine, provides important evidence on the adequacy of antifungal drug exposure in critically ill patients, an area where dosing guidance remains limited.

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Richard's experience from his recent visit.

Brisbane Transplant Infectious Diseases Meeting brings cross-disciplinary insights to the forefront of patient care

CRE RESPOND’s Population Pharmacokinetics Workshop returns to Brisbane this July

Research Fellow

Research Fellow and Pharmacokinetic Analyst

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Matthieu's experience from his recent visit.

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Camilla's experience from her recent visit.

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about María's experience from her recent visit.

Resistance Optimised Antibiotic Dosing (The ROAD Study): Is dosing of meropenem and piperacillin-tazobactam optimised to prevent the emergence of antibiotic resistance safe and feasible in the ICU? A pilot study.

Antimicrobial stability is an important consideration for treatment planning and service delivery in outpatient parenteral antimicrobial therapy (OPAT) programmes. Regulation of stability assessment varies by region, and conflicting guidance and standards exist. This leads to disparity of equity in access and limits availability of certain antimicrobials for managing infections in the outpatient setting.